Drreddys Laboratories | RDY - Operating Profit


Drreddys Laboratories reported INR829M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
ANI Pharmaceuticals USD 39.84M 1.13M Jun/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
Bayer EUR 827M 2.7B Jun/2026
Canopy Growth CAD -27.47M 14.81M Mar/2026
Cipla INR 8.88B 2.74B Jun/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Drreddys Laboratories INR 829M 13.5B Mar/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lonza CHF 673M 243M Jun/2025
Novartis USD 4.75B 515M Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Richter Gedeon HUF 62.32B 1.26B Mar/2026
Sun Pharmaceuticals INR 35.57B 8.05B Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026